We're on the cusp of a significant new era in medical device design, Nano Surfaces CEO Joe Gatto tells MassDevice, in which their very surfaces will build themselves and be able to operate at the molecular level.
Coming generations of implanted medical devices will interact with the human body at the molecular level, using sophisticated nano-coatings to not only thwart microbial growth but to perform biological operations.
That's the prediction of Nano Surfaces founder, president and CEO Joe Gatto. The Boston-based firm is developing technology it's licensed from Cornell University to create self-assembling, anti-microbial coatings on a nanotech scale — and Gatto says that's just the beginning. To prove it, he's hitting to road to raise a Series A round from institutional investors.
To mimic cells' physiologic features, scientists work at the nanoscale – creating structures at the range of 1 billionth of a meter, 100 times smaller than a red blood cell.
By Tal Dvir
As tissue engineers, we seek to develop functioning substitutes for damaged tissues and organs. Generally, this means seeding cells onto 3-dimensional porous scaffolds made of biomaterials, which provide mechanical support and instructive cues for the developing engineered tissue. Now it’s time to go to the next level, and make complex tissues that can really do things (PDF) — contract, release growth factors, conduct electrical signals and more. Things our own cells and tissues do.
Semprus Biosciences Corp. closes an $18 million Series B funding round, which CEO David Lucchino says it will use to build out its management team and fund manfuacturing ramp-up for its nanotech catheter coating.
Semprus BioSciences Corp. reeled in $18 million in Series B financing for its nanotech medical device coating.
Semprus CEO David Lucchino told MassDevice that the company will use the proceeds to build a team of "been there, done that" medical device executives and to scale up its manufacturing operations.
"Investor expectations with this round of funding are that we would gain regulatory and clinicial clarity, along with having an initial product in hand to start initial sales. We're looking at the next 24 months as being that window," Lucchino told us.
Audax Medical Inc. inks an exclusive license agreement with Brown University for Arxis, a biomaterial that the two are developing for regenerative medicine applications.
Audax Medical Inc. entered into partnership deal with Brown University for a nanotechnology-based biomaterial for regenerative medicine.
The licensing agreement gives the Littleton, Mass.-based company exclusive rights to Arxis, which is based on an organic osteobiologic developed at the university's School of Engineering and Dept. of Orthopedics.
Scientists track air as we breath it; computer mouse measures blood pressure; brain probe stimulates individual neurons, nanogenerators power implantable devices.
Scientists track air as we breath it: Investigators at Beth Israel Deaconess Medical Center and the Harvard School of Public Health have been using a locally developed system to track near-infrared fluorescent nanoparticles as they enter and leave the lungs.
Tennessee diagnostic device company NanoDetection Technology is moving to Cincinnati.
Lured by an anticipated $2 million investment round, Tennessee diagnostic device company NanoDetection Technology is moving to Cincinnati.
The new funding will allow the company to complete the clinical trials necessary to get its device on the market, which NanoDetection hopes to do by 2013, according to a statement from CincyTech, a public-private investment group that contributed $250,000 to the deal. The group obtains funding through Ohio's Third Frontier initiative, which is designed to support high-tech jobs in the state.
Nano-sized objects that can swim; American Medical Association opens news service to public; economist proposes resistance index for bacteria; solar powered blood pressure device tested in rural Africa.
Nano-sized objects that swim: One way to deliver nanomedicines is to inject particles directly into target tissue or infuse them into the blood stream for systemic administration. The other approach is to develop particles that can move or swim through a medium.